Toripalimab
CHS-007-01/RTOG 3521
Approved small_molecule active
Quick answer
Toripalimab for Nasopharyngeal Cancer Recurrent is a Approved program (small_molecule) at Coherus Oncology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Coherus Oncology
- Indication
- Nasopharyngeal Cancer Recurrent
- Phase
- Approved
- Modality
- small_molecule
- Status
- active